Looking for early warning signs of worsening in liver cirrhosis
Studies hospital records to find what predicts serious decline in adults with cirrhosis.
Key facts
- Who runs it
- Singapore General Hospital
- Where
- Singapore3 sites in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Predictors of Decompensation, Acute-on-chronic Liver Failure and Mortality in Liver Cirrhosis
- Status
- Recruiting
- People taking part
- 2,200 people, planned
- Started
- 12 Aug 2022
- Expected to end
- 12 Aug 2032
- Type of study
- Observational
- Treatments tested
- Observation
- Record updated
- 27 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with liver cirrhosis (scarring of the liver). It only collects data from hospital records, with no extra visits or tests.
- Age
- 18 years and above. Parental consent is needed if below 21 years.
- Sex
- All sexes can join.
- Disease stage
- A clinical diagnosis of liver cirrhosis.
Main reasons for not taking part
- No clinical evidence of liver cirrhosis
- Not willing to give informed consent
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patients with clinical diagnosis of liver cirrhosis
- Age 18 years and above (parental consent required if below 21 years)
- Willing and able to provide informed consent
Who cannot take part
- No clinical evidence of liver cirrhosis
- Not willing to provide informed consent
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The purpose of this study is to identify factors that predict the development of decompensation, acute-on-chronic liver failure (ACLF) and death in patients with liver cirrhosis. Clinical data will be retrieved from existing hospital records. This information may help doctors to identify patients with cirrhosis who are at risk of deterioration earlier (before they develop complications) and to develop effective treatment strategies to prevent or delay these complications.
Read full original descriptionShow less
This study is designed as a prospective, non-interventional, observational study. This means that if you agree to participate in the study, you will not be required to undergo any additional hospital visits, tests, procedures or interventions other than the usual standard-of-care management that your doctor will provide. If you consent to participate in this study, you will be providing the study investigators permission to review and analyse your clinical data from the hospital clinical records. Your data will be collected throughout the course of your disease until liver transplantation or death.
The group in the trial
- Patients with liver cirrhosis
Treatment: Observation
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Predictors of Decompensation, Acute-on-chronic Liver Failure and Mortality in Liver Cirrhosis - a Multicentre, Prospective, Observational Study From the SingHealth Chronic Liver Disease Registry (SoLiDaRity-DAM)
- Plain-language title
- Looking for early warning signs of worsening in liver cirrhosisGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 27 February 2026